Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16084082 | 0.85 | PKLR (1.00) | PKLR | |
| SCHEMBL21976134 | 0.81 | PKLR (0.69) | PKLR | |
| SCHEMBL16049574 | 0.81 | PKLR (1.00) | PKLR | |
| SCHEMBL17826386 | 0.80 | PKLR (0.71) | PKLR | |
| SCHEMBL16049623 | 0.79 | PKLR (1.00) | PKLR | |
| SCHEMBL16049820 | 0.79 | PKLR (1.00) | PKLR | |
| SCHEMBL16084027 | 0.79 | PKLR (0.70) | PKLR | |
| SCHEMBL16049613 | 0.79 | PKLR (0.81) | PKLR | |
| SCHEMBL16083908 | 0.79 | PKLR (0.89) | PKLR | |
| SCHEMBL16049619 | 0.79 | PKLR (0.78) | PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2016-02-18 | — | — | US | disclosed |
| EP-2970189-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014139325-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139325-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | PKLR 19/4885 |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | PKLR 14/4885 |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | PKLR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.